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Simple Summary: Acute myeloid leukemia (AML) is one of several cancers where cancer proliferation
occurs under the influence of an aberrant metabolite known as an oncometabolite produced by
a mutated enzyme in the cancer cell. In AML, mutant isocitrate dehydrogenases produce the
oncometabolite 2-hydroxyglutarate. We screened AML patients with and without mutant isocitrate
dehydrogenases by using a technique known as metabolomics, which measures many different
metabolites in patient plasma. It was observed that another metabolite, 2,3-dihydroxybutyrate,
was produced in larger amounts in patients with mutated isocitrate dehydrogenase and correlated
strongly with 2-hydroxyglutarate levels. Moreover, 2,3-dihydroxybutyrate was a better indicator
of the presence of mutated isocitrate dehydrogenase in the cancer than the known oncometabolite
2-hydroxyglutarate. These findings may lead to the characterization of 2,3-dihydroxybutyrate as
a novel oncometabolite in AML, which would bring a fuller understanding of the etiology of this
disease and offer opportunities for the development of novel therapeutic agents.
Abstract: Acute myeloid leukemia (AML) frequently harbors mutations in isocitrate 1 (IDH1) and
2 (IDH2) genes, leading to the formation of the oncometabolite (2R)-hydroxyglutaric acid (2R-HG)
with epigenetic consequences for AML proliferation and differentiation. To investigate if broad
metabolic aberrations may result from IDH1 and IDH2 mutations in AML, plasma metabolomics
was conducted by gas chromatography–mass spectrometry (GC–MS) on 51 AML patients, 29 IDH1/2
wild-type (WT), 9 with IDH1R132, 12 with IDH2R140 and one with IDH2R172 mutations. Distinct
metabolic differences were observed between IDH1/2 WT, IDH1R132 and IDH2R140 patients that
comprised 22 plasma metabolites that were mainly amino acids. Only two plasma metabolites were
statistically significantly different (p < 0.0001) between both IDH1R132 and WT IDH1/2 and IDH2R140
and WT IDH1/2, specifically (2R)-hydroxyglutaric acid (2R-HG) and the threonine metabolite
(2R,3S)-dihydroxybutanoic acid (2,3-DHBA). Moreover, 2R-HG correlated strongly (p < 0.0001) with
2,3-DHBA in plasma. One WT patient was discovered to have a D-2-hydroxyglutarate dehydrogenase
(D2HGDH) A426T inactivating mutation but this had little influence on 2R-HG and 2,3-DHBA plasma
concentrations. Expression of transporter genes SLC16A1 and SLC16A3 displayed a weak correlation
with 2R-HG but not 2,3-DHBA plasma concentrations. Receiver operating characteristic (ROC)
analysis demonstrated that 2,3-DHBA was a better biomarker for IDH mutation than 2R-HG (Area
under the curve (AUC) 0.861; p < 0.0001; 80% specificity; 87.3% sensitivity). It was concluded that
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2,3-DHBA and 2R-HG are both formed by mutant IDH1R132, IDH2R140 and IDH2R172, suggesting
a potential role of 2,3-DHBA in AML pathogenesis.
Keywords: acute myeloid leukemia; isocitrate dehydrogenase 1; isocitrate dehydrogenase 2;
metabolomics; biomarker; (2R)-hydroxyglutaric acid; (2R,3S)-dihydroxybutanoic acid; oncometabolite
1. Introduction
Almost a century ago, Otto Warburg described experiments that established the first metabolic
anomaly in tumors that was distinct from cells in normal tissues, a preference for the fermentation of
glucose to lactate by aerobic glycolysis [1,2], subsequently to become known as the Warburg effect [3].
With the characterization of nucleic acids in the 1950s and the subsequent discovery of oncogenes
and tumor suppressor genes, the role of aerobic glycolysis might play in oncogenesis began to draw
less attention. Furthermore, aerobic glycolysis was viewed as an inefficient means of ATP generation
compared to mitochondrial oxidation and therefore the advantage of glycolytic metabolism to the
tumor was unclear. Nevertheless, tumor glycolysis can occur independently of oxygen and produce
ATP at a rate 10–100 times faster than that by mitochondrial oxidation. However, the recognition that
cancer cell metabolism is tailored to enable the conversion of nutrients into the lipids, amino acids and
nucleotides needed for the generation of a new cell, moved the focus from efficiency of ATP production
to the metabolism of nutrients into cellular building blocks. It was recognized that proliferating
cells must switch from carbon catabolism for ATP production to the synthesis of the macromolecular
precursors acetyl-CoA, non-essential amino acids, and ribose [3]. In addition, the uncovering of the
mechanism by which the Krebs cycle enzymes fumarate hydratase and succinate dehydrogenase could
function as tumor suppressors [4] helped place energy metabolism at the center of cancer biology.
Given the foregoing, it is surprising that relatively few endogenous metabolic pathways have been
recognized as essential elements of oncogenesis. Nevertheless, reprogramming of energy metabolism
has been added to the hallmarks of cancer [5]. However, it would be work on two other Krebs cycle
intermediates, isocitrate and 2-oxoglutarate (2-OG), in particular in glioma and acute myeloid leukemia
(AML), that would lead to the concept of an “oncometabolite”.
A genome-wide analysis of gliomas revealed mutations in the isocitrate dehydrogenase genes
IDH1 and IDH2 that diminished the NADP-dependent conversion of isocitrate to 2-OG when expressed
in cell culture [6]. Mutant IDH1 and IDH2 also occur in AML, which is invariably heterozygous for these
IDH mutations and so retains functional isocitrate metabolism [7]. It has been stated that IDH1 and IDH2
mutations are mutually exclusive in AML [8–10]. However, this does not preclude the occurrence of
rare cases bearing both mutations detected in particular with the use of next-generation sequencing [11].
The mutant neomorphic IDH enzyme, in contrast to the wild-type (WT) enzyme, converts 2-OG
to (2R)-hydroxyglutaric acid (2R-HG; D-2-hydroxyglutaric acid) that can accumulate to 10 mM
concentration or greater [12] and was thought to contribute to leukemogenesis [7,13]. Subsequently,
it was reported that 2R-HG producing cells displayed global DNA hypermethylation, a specific
hypermethylation signature, harbored impaired DNA demethylase TET2 catalytic function [14],
with inhibition of 2-OG-dependent chromatin-modifying enzymes, including JmjC histone lysine
demethylases [15]. As a consequence, these effects of 2R-HG that alter the epigenetic landscape of both
AML [16] and of glioma [17] resulted in 2R-HG being labeled as an oncometabolite [7].
Metabolomics is a powerful tool for the examination of cancer metabolism [18]. We have recently
reviewed the history of metabolomics and its potential for uncovering disease biomarkers [19,20].
Using three separate mass spectrometry-based lipidomic platforms, we have reported a detailed
metabolomic investigation of the plasma lipid profile of AML [21]. We found a decline in sphingolipids,
phosphocholines, triglycerides and cholesterol esters probably due to enhanced fatty acid oxidation
in AML cells. Arachidonic acid and its precursors were elevated in AML, predominantly in patients
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with a high number of blasts in bone marrow or blood and an adverse prognostic risk. PGF2α was
also elevated but in patients with low blast counts in bone marrow or blood and with a favorable
prognostic risk. A wide range of individual lipids were therefore altered in AML patient plasma
compared to healthy controls. A number of metabolomic and lipidomic investigations in AML have
been reported [22–30] and these have been recently reviewed [31]. None of these studies addressed the
changes to the plasma metabolome conferred by mutated IDH1 and IDH2. It is understood that such
mutations result in production of the oncometabolite 2R-HG. However, what is not known is what
additional primary or secondary metabolic changes are a consequence of IDH gene mutation and may
contribute to the pathogenesis of AML and/or its resistance to chemotherapy.
The purpose of this study was to define metabolic changes visible in the plasma of AML patients as
a result of IDH gene mutation. Towards this aim, we have conducted an investigation of AML patients
with and without mutations at IDH1R132, IDH2R140 and IDH2R172 using gas chromatography–mass
spectrometry (GC–MS) metabolomics with multivariate and univariate data analysis. It is concluded
that mutations at IDH1R132 and IDH2R140 have differential effects on the plasma metabolome and that
both 2R-HG and the threonine metabolite (2R,3S)-dihydroxybutanoic acid (2,3-DHBA; 4-deoxthreonic
acid) were elevated in plasma as a result of IDH1 or IDH2 mutation. Furthermore, these two metabolites
were highly correlated, strongly suggesting that not only 2R-HG but also 2,3-DHBA is produced by
mutant IDH.
2. Results
2.1. Metabolomic Analysis
Plasma samples were analyzed in triplicate by GC–MS and a total of 67 chromatographic peaks
were identified using the NIST 14 spectral library and an in-house library of 120 authentic standards.
Six metabolites each appeared as two peaks due to multiple derivatives and these concentrations were
summed to yield relative concentrations for 60 identified metabolites that were subjected to multivariate
data analysis using orthogonal projection to latent structures-discriminant analysis (OPLS-DA) [32].
2.1.1. Comparison of AML Patients with WT IDH1/2, Mutated IDH1 and Mutated IDH2
Metabolite plasma concentrations were compared for nine patients with IDH1R132 mutations
and 12 with IDH2R140 mutations using OPLS-DA. Figure 1A shows the OPLS-DA scores plot for this
comparison. Two metabolic phenotypes are visible corresponding to IDH1R132 and IDH2R140. It is
clear that the mutation of IDH2 had a more profound effect on cellular metabolism than the mutation
of IDH1, with 21 elevated plasma metabolites compared to only one elevated metabolite for IDH1
mutation. Table 1 itemizes the metabolic differences between WT and mutations of IDH1 and IDH2.
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Figure 1. Plasma metabolomic analysis of acute myeloid leukemia (AML) patients with IDH1R132
versus IDHR140 mutations and wild-type (WT) IDH1/2 patients versus mutated IDH1/2. (A) Orthogonal
projection to latent structures-discriminant analysis (OPLS-DA) scores plot for IDH1R132 (yellow) versus
IDHR140 (burgundy) showing clustering and partial separation of the two metabolic phenotypes.
t[1] and t0[1] are the first principal component and the first orthogonal component, respectively.
(B) OPLS-DA loadings S-plot showing the up- and down-regulated plasma metabolites responsible for
the separation in scores in (A). Upper right and lower left quadrants represent the metabolites that are
upregulated in IDH1 mutant plasma and IDH2 mutant plasma, respectively. Metabolites labeled 1 to
22 correspond to those listed in Table 1. p[1] and p(corr)[1] are related to relative concentration and
correlation to the model, respectively. (C) OPLS-DA loadings S-plot showing the upregulated plasma
metabolites in WT IDH1/IDH2 (upper right quadrant) and mutant IDH1/IDH2 (lower left quadrant)
AML patients. Note that only two statistically significantly different metabolites were found between
WT and mutant AML plasmas, 2R-HG, as expected, and the unexpected finding of 2,3-DHBA.
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Table 1. Plasma metabolite relative concentration (metabolite peak area/internal standard peak
area) differences between wild-type AML patients and those with IDH1R132 and IDH2R140
mutations. The three groups were compared using nonparametric ANOVA (Kruskal–Wallis test)
with p-values given.
# Metabolite
Median Relative
Concentration
Wild-Type IDH1/2
Median Relative
Concentration
IDH1R132
Median Relative
Concentration
IDH2R140
p-Value
1 galactose 541 372 595 <0.0001
2 mannose 265 170 302 <0.0001
3 xylitol 0.6 0.3 0.8 <0.0001
4 alanine 14.7 7.7 23.5 <0.0001
5 valine 32.4 26.4 47.6 <0.0001
6 leucine 29.1 23.8 38.4 <0.0001
7 isoleucine 10.2 7.9 14.0 <0.0001
8 proline 17.2 9.3 20.3 <0.0001
9 tyrosine 20.2 14.4 26.9 <0.0001
10 glutamine 8.2 3.7 9.2 <0.0001
11 phenylalanine 11.5 9.4 12.5 <0.0001
12 tryptophan 12 8.6 16.5 0.0002
13 methionine 1.8 1.2 2.2 <0.0001
14 lysine 0.6 0.3 1.1 <0.0001
15 glutamic acid 0.8 0.5 1.2 <0.0001
16 ornithine 0.2 0.1 0.4 <0.0001
17 ethanolamine 14.5 9.2 20.2 <0.0001
18 carbamic acid 1 3.6 3.1 3.8 <0.0001
19 threonine 6.2 4.0 7.7 0.0001
20 hexanoic acid 0.8 0.8 0.7 0.001
21 urea 965.4 285 1051 0.02
22 serine 7.2 3.9 8.9 <0.0001
1 Formed from carbamoyl phosphate by thermal decomposition [33].
Interestingly, 14 α-amino acids were varied highly statistically significantly in these three IDH
genotypes. The general pattern of amino acid changes was that they were lower in IDH1R132 than
IDH1/2 wild types but higher in IDH2R140 than wild types. The same pattern was found with all the
other metabolites listed in Table 1, except hexanoic acid. The OPLS-DA loadings S-plot (Figure 1B)
shows the relative abundance of the plasma metabolites as measured on the abscissa by p[1] that
indicates that urea (#21), mannose (#2) and galactose (#3) were the most abundant plasma metabolites
resulting from IDH2 mutation. In contrast, hexanoic acid associated with IDH1 mutation appeared to
be a relatively minor metabolite based upon its p[1] value (Figure 1B) and its relative concentration
in Table 1. The relative abundance of the α-amino acids in IDH2R140 plasma is unrelated to their
natural abundance genome wide in human proteins, where leucine has the highest abundance (9.97%)
and tryptophan the lowest (1.22%) [34]. It is unlikely therefore that these α-amino acids derive from
nonspecific proteolysis. However, an altered plasma profile of free amino acids in AML has been
previously reported, with elevated glutamate, tryptophan, ornithine, and glycine relative to the plasma
of healthy control subjects. In addition, plasma serine, methionine, and taurine concentrations were
lower in AML than in control plasma [35]. This same group reported elevated plasma glutamate and
tryptophan in both lung and breast cancer patients [36]. Unlike the previous report [35], plasma samples
in the current investigation were not collected under fasting conditions.
2.1.2. Comparison of AML Patients with Wild-Type IDH1/2 and Mutated IDH1/IDH2
Metabolomic analysis was conducted on 29 AML patients with WT IDH1/2 compared to 21 AML
patients with IDH1R132 and IDH2R140 mutations. The OPLS-DA loadings S-plot is shown in Figure 1C.
No plasma metabolites were statistically significantly elevated in WT patients but those bearing
IDH1R132 or IDH2R140 mutations had two statistically significantly elevated plasma metabolites,
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the expected 2R-HG (p < 0.0001) and the unexpected finding of 2,3-DHBA (p < 0.0001). Figure 2 shows
the distribution of relative concentration in plasma for both these plasma metabolites in WT IDH1/2
AML patients and mutant IDH1/2 patients.
Figure 2. Plasma concentrations of (A) (2R)-hydroxyglutaric acid and (B) (2R,3S)-dihydroxybutanoic
acid in patients with WT and mutant IDH1/2. Red horizontal lines represent median values and
distributions were compared using the nonparametric Mann–Whitney test. Note the similar distribution
of these two metabolites and the presence of outliers in the IDH1/2 WT genotypes, suggesting the
presence of mutations additional to IDH1R132 and IDH2R140 that were not determined.
To investigate the potential relationship between 2R-HG and 2,3-DHBA, correlation between these
two metabolites was conducted and, as negative controls, between 2R-HG and glutamate and 2R-HG
and (3S)-methyl-2-oxovaleric acid (3M2OVA) (Figure 3).
Figure 3. Correlations between (2R)-hydroxyglutarate and (A) (2R,3S)-dihydroxybutanoic acid,
(B) glutamate, and (C) (3S)-methyl-2-oxovaleric acid. Correlation analysis was conducted using the
nonparametric Spearman rank correlation, which was highly significant for (2R)-hydroxyglutarate and
(2R,3S)-dihydroxybutanoic acid (rs = 0.569; p < 0.0001) but not significant (N.S.) for either glutamate or
(3S)-methyl-2-oxovaleric acid.
The two negative controls were chosen because the 2R-HG precursor 2-OG undergoes
transamination with the branched-chain amino acids valine, leucine, and isoleucine mediated by
branched-chain amino acid transaminase 1 and 2 (BCAT1 and BCAT2). The transaminase reaction
between 2-OG and isoleucine produces glutamate and 3M2OVA (α-keto-β-methylvalerate; KMV) [37]
(see Figure 4). In an apparently unrelated pathway, threonine undergoes transamination/deamination
to (3S)-hydroxy-2-oxobutanoic acid, which is further reduced stereospecifically to 2,3-DHBA (also
known as 4-deoxythreonic acid) in an uncharacterized reaction [38,39]. Nuclear magnetic resonance
studies also showed that the (2R,3R)-diastereomer (4-deoxyerythronic acid) was not present in normal
human urine [39]. An earlier report stated that 4-deoxythreonic acid was present in large amounts in
human urine compared to 4-deoxyerythronic acid [40].
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Figure 4. Metabolic pathways showing the formation of (A) 2R-HG from 2-OG by mutant IDH1
and IDH2 with the transamination of 2-OG with isoleucine by BCAT1 and BCAT2 to glutamate and
2M3OVA. (B) The transamination and reduction of threonine to 2,3-DHBA with the participation of
2,3-DHBA.
The catabolism of threonine is generally considered to proceed by threonine-ammonia lyase
[EC 4.3.1.19] to 2-oxobutanoic acid (α-ketobutyrate) (Figure 4B) [41], which can be further utilized
to synthesize isoleucine [42]. However, threonine can undergo transamination [41], which produces
(3S)-hydroxy-2-oxobutanoic acid (α-keto-β-hydroxybutyrate; Figure 4B) [39]. Additionally, studies
with [13C] threonine in the dog established that 2,3-DHBA derived from threonine [38]. The data
and analyses presented here indicate that the final step in the synthesis of 2,3-DHBA is conducted by
mutant IDH1 and/or IDH2 in parallel to the synthesis of 2R-HG.
2.1.3. Comparison of WT vs. IDH1R132 and WT vs. IDH2R140 and the Effect of D2HGDH
Polymorphism on 2R-HG and 2,3-DHBA Plasma Levels
Figure 2 shows that AML patients with IDH1/2 mutations had highly statistically significantly
elevated plasma concentrations of both 2R-HG and 2,3-DHBA. However, it was notable that certain
patients with WT IDH1/2 displayed high plasma concentrations of both 2R-HG (Figure 2A) and
2,3-DHBA (Figure 2B). In order to establish if these high plasma levels derived from IDH1 or IDH2,
we conducted a separate analysis of WT vs. IDH1R132 and IDH2R140 (Figure 5). During this analysis,
we noted that the single IDH2R172 patient had a higher plasma concentration of both 2R-HG and
2,3-DHBA than any IDH1/2 WT patient and the vast majority of the IDH1R132 and IDH2R140 patients
(see Table S2). 2R-HG plasma concentrations were higher for the IDH2R172 patient than the IDH1/2
WT patients (p < 0.0001) and also greater than the IDH2R140 patients (p = 0.047). Moreover, 2,3-DHBA
plasma concentrations were higher in the IDH2R172 patient than in either the IDH1R132 (p = 0.034) or
IDH2R140 (p = 0.007) patients. It is concluded that the IDHR172 mutant neomorphic enzyme has a
high activity with respect to the production of both 2R-HG and 2,3-DHBA. In addition, an analysis of
six known mutant alleles [43,44] of the D-2-hydroxyglutarate dehydrogenase gene (D2HGDH) was
conducted in WT patients by PCR. D2HGDH catalyzes the back reaction from 2R-HG to 2-OG [43].
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Only one WT patient was found to have a D2HGDH mutation (A426T) but had unremarkable plasma
concentrations of 2R-HG and 2,3-DHBA (see Tables S1 and S2). In addition, we examined D2HGDH
mRNA expression in 46/51 patients with sufficient RNA. D2HGDH expression normalized to ABL1
expression was unrelated to metabolite plasma concentrations of either 2R-HG or 2,3-DHBA (Figure S1)
by Spearman rank correlation. These findings make it unlikely that D2HGDH activity, which mediates
the conversion of 2R-HG back to 2-OG, has a dominant influence on plasma concentrations of either
2R-HG or 2,3-DHBA. This presumably remains due to mutated IDH.
Figure 5. Statistical analysis of (A) 2R-HG and (B) 2,3-DHBA plasma concentrations in WT vs.
IDH1R132 and WT vs. IDH2R140 AML patients. Both comparisons showed statistically significant
differences (p < 0.0001) by the nonparametric Mann–Whitney test, while plasma concentrations in
IDH1R132 and IDH2R140 patients were not statistically significant (p > 0.7). Red horizontal lines
represent median values in each group. All patients are represented by triplicate plasma analyses
by GC–MS.
The issue of the compartmentalization of 2R-HG and 2,3-DHBA was addressed because
these metabolites are produced intracellularly but were determined in the plasma compartment.
The expression of four transporter genes (SLC16A1, SLC16A3, SLC22A6 and SLC22A8) was determined,
normalized against ABL1 expression. These were considered to be candidate transporters for the
export of 2R-HG and 2,3-DHBA into plasma as both monocarboxylate transporters (MCT1 and MCT4)
and organic anion transporters (OAT1 and OAT3). There was a weak and barely statistically significant
negative concentration (p = 0.04) between both SLC16A1 and SLC16A3 expression and 2R-HG plasma
concentration (Figure S2). The expression of these two transporters did not correlate with 2,3-DHBA
plasma concentration. Neither SLC22A6 or SLC22A8 had detectable mRNA expression. The SLC16A1
and SLC16A3 findings are counterintuitive and may have no bearing on function because SLC16A1
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(MCT1) is typically considered to be an importer from plasma and SLC16A3 (MCT4) is regarded as an
exporter from cells to plasma [45].
2.1.4. Biomarker Evaluation
It is to be expected that 2R-HG would act as a biomarker for mutations in IDH1/2 as it is apparently
only produced from 2-OG by the neomorphic IDH enzymes arising from mutated IDH1/2 [7]. However,
its utility as a biomarker for mutation of isocitrate dehydrogenase has not been evaluated in AML.
Figure 2 clearly shows that there are AML patients without IDH1R132 and IDH2R140 mutations
that have elevated plasma 2R-HG concentrations. These patients were assumed to be WT for IDH1
and IDH2. It is possible that they bear other mutations. The known IDH mutations leading to the
neomorphic enzyme all occur at the arginine residues IDH1R132, IDH2R140, and IDH2R172 [46].
Different mutations at these arginine residues have been reported to give rise to varying yields of
2R-HG over a nine-fold range in U87MG glioblastoma cells in culture, with IDH2R172M (Arg→Met) >
IDH2R172K (Arg→Lys) > IDHR140Q (Arg→Glu). Cells expressing these mutated IDH enzymes have
2R-HG production determined by GC–MS that was 15- to 150-fold greater that cells expressing the WT
enzyme [47]. We therefore examined the extent to which 2R-HG plasma concentration could act as a
biomarker for IDH1/2 gene mutation by using ROC analysis. In addition, if 2,3-DHBA is produced by
IDH1R132 and IDH2140, then this metabolite should also be a biomarker for IDH1/2 gene mutation
when subjected to ROC analysis. As a negative control, plasma 3M2OVA concentrations were also
utilized for ROC analysis.
The ROC analysis in Figure 6 further implicates mutant isocitrate dehydrogenase as the source of
2,3-DHBA in AML.
Figure 6. Receiver Operating Characteristic (ROC) curves for (A) plasma (2R)-hydroxyglutaric acid
(2R-HG), (B) plasma (2R,3S)-dihydroxybutanoic acid (2,3-DHBA), and (C) (3S)-methyl-2-oxovaleric
acid (3M2OVA) for mutant IDH1R132 and IDH2R140 vs. WT IDH1/2. Both plasma 2R-HG and plasma
2,3-DHBA highly statistically significantly (p < 0.0001) detected AML patients with IDH mutations,
while plasma 3M2OVA did not. Note that at 80% specificity, plasma 2,3-DHBA had a better sensitivity
(87.3%) than 2R-HG (63.8%).
2.1.5. Relationship of (2R)-Hydroxyglutaric Acid and (2R,3S)-Dihydroxybutanoic Acid to Clinical
Variables of AML
Using multivariate analysis, we examined if the plasma concentrations of 2R-HG or 2,3-DHBA
were related to prognostic risk (favorable, intermediate or adverse), plasma fibrinogen concentration,
normal karyotype vs. aneuploidy, and FAB classification M0/M1/M2 vs. M4/M5/M6 at time of diagnosis
(see Table S1). Plasma concentrations of 2R-HG were not related any of these variables associated
with clinical outcome. However, plasma 2,3-DHBA was found to be 1.8-fold higher (p = 0.001) in
patients with high plasma fibrinogen (≥4.1 g/L) relative to those with plasma fibrinogen concentrations
in the normal range (<4.1 g/L). Patients with a plasma fibrinogen ≥4.1 g/L determined at the time of
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diagnosis have been reported to have poorer progression-free and overall survival [48]. This suggests
that elevated plasma 2,3-DHBA, but not plasma 2R-HG, may be related to poorer survival.
Multiple plasma metabolites, but not the oncometabolite 2R-HG, were found to be related to
prognostic risk (favorable, intermediate or adverse), plasma fibrinogen concentration, normal karyotype
vs. aneuploidy, and FAB classification M0/M1/M2 vs. M4/M5/M6 at time of diagnosis (Table S3).
3. Discussion
Cancer metabolism is now a recognized hallmark of cancer [5]. The function of cellular metabolism
in normal tissues is mainly concerned with the generation of energy through the breakdown
of carbohydrates, fats, and amino acids and with the production of the building blocks such as
phospholipids and nucleotides that are required for growth. In cancer cells, these metabolic processes
are reprogrammed under multiple influences that include mutated oncogenes and tumor suppressor
genes in order to support the proliferative cancer phenotype. The development of the field of
metabolomics has permitted many novel insights into cancer metabolism, including oncogenic drivers
of metabolic reprogramming [49], transcriptional regulators of metabolic rewiring in cancer cell
lines [50], and abnormally expressed metabolic pathways in tumors [51].
In this investigation in AML patients, we have utilized plasma metabolomics to examine the
metabolic consequences of IDH1 and IDH2 genotype determined from either peripheral blood
mononuclear cells (PBMCs) or bone marrow mononuclear cells (BMMCs). As was to be expected,
plasma 2R-HG concentration was greater in patients harboring mutations at either IDH1R132 or
IDH2R140, since the neomorphic IDH enzyme they produce is responsible for synthesis of 2R-HG from
2-OG. Somewhat surprisingly, the difference between WT and mutated IDH1/2 in plasma 2R-HG levels,
although highly statistically significant (p < 0.0001), was determined to be only 7-fold. It is understood
that 2R-HG is produced within leukemic cells that bear the IDH1/2 mutations, which is a different
compartment from the plasma that was subjected to metabolomic analysis. We did not collect either
PBMCs or BMMCs for metabolomic analysis. It is probable that 2R-HG diffused or was transported
from its site of production in leukemic cells into plasma. The expression of plasma membrane outward
transporters in AML cells has not been characterized. The cellular export of 2R-HG might be expected to
be elicited by the organic ion transporters 1 and 3 (OAT1 and OAT3, encoded by SLC22A6 and SLC22A8,
respectively), which mediate the cellular efflux of 2-OG [52], but the occurrence of these transporters in
AML cells or their transport of 2R-HG have not been reported. Furthermore, the monocarboxylate
transporters 1 and 4 (MCT1 and MCT4, encoded by SLC16A1 and SLC16A3, respectively) that are
typically overexpressed in glioblastomas, are underexpressed or silenced in glioblastomas that possess
IDH1 mutations. MCT1 and MCT4 typically uptake pyruvate and export lactate in tumor cells [53].
However, whether or not these transporters can move 2R-HG in or out of cells is currently unknown.
Nevertheless, we examined the mRNA expression of four SLC transporter genes, namely, SLC16A1,
SLC16A3, SLC22A6 and SLC22A8. Neither of these last two transporters was expressed in the PBMCs
studied. The weak negative and barely statistically significant correlation (p = 0.04) between SLC16A1
and SLC16A3 expression with 2R-HG plasma concentration did not explain the unexpectedly small
difference between WT and mutant IDH1/2 in 2R-HG plasma concentration.
Next we examined if the mere 7-fold plasma concentration difference between IDH1/2 mutated
and WT AML patients was due to differential expression of D-2-hydroxyglutarate dehydrogenase
(D2HGDH; EC 1.1.99.39), which catalyzes the reverse reaction of 2R-HG to 2-OG. There are known
mutations in the D2HGDH gene leading to an inert enzyme. High expression of D2HGDH has
also been found in head and neck squamous cell carcinoma (HNSCC), where it was reported to be
a protective factor conferring low risk [54]. To date, the expression of D2HGDH in AML has not
been reported, but as with HNSCC, it is possible that a high expression D2HGDH phenotype exists,
which, if associated with IDH1/2, might explain the meager 7-fold difference in median plasma 2R-HG
between mutated and WT IDH. In fact, Figure 2A shows considerable interpatient variability in
plasma 2R-HG relative concentration in mutant IDH1/2 patients with 40% of the WT patients but
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none of the mutant IDH1/2 patients having values of zero or close to zero (≤ 0.1). For these reasons,
we conducted the genotyping of six known inactivating D2HGDH alleles [43,44] in IDH1/2 WT AML
patients. Only one inactivating mutation (A426T) was detected and in only one WT AML patient.
However, this inactivating D2HGDH allele was associated with unremarkable plasma concentrations
of both 2R-HG and 2,3-DHBA in that patient. Other as yet unreported D2HGDH inactivating alleles
may explain why a few other IDH1/2 WT AML patients displayed elevated plasma concentrations
of both 2R-HG and 2,3-DHBA. It should be noted that 2R-HG and its enantiomer 2S-HG are normal
metabolites found in human body fluids [55] that are produced at low levels by mitochondrial alcohol
dehydrogenase iron containing 1 (ADHFE1; EC 1.1.99.24) [56,57]. The mRNA expression of D2HGDH
was then examined in 46/51 AML patients. No statistically significant correlations were found between
D2HGDH expression and either 2R-HG or 2,3-DHBA plasma concentrations. It must be concluded that
mutant IDH1/2 metabolic activity rather than D2HGDH is responsible for plasma levels of 2R-HG and
2,3-DHBA.
The finding that plasma 2,3-DHBA levels were also highly statistically significantly (p < 0.0001)
elevated in AML patients with IDH1/2 mutations compared to WT (Figure 2B) was unexpected.
Moreover, plasma levels of 2R-HG and 2,3-DHBA were highly statistically significantly correlated
(rs = 0.569, p < 0.0001; Figure 3A). No correlation was found between 2R-HG and either glutamic acid
(Figure 3B) or 3M2OVA (Figure 3C), which, like 2R-HG, can also be formed from 2-OG (Figure 4A).
Finally, when examining WT and mutant IDH1/2 using ROC analysis (Figure 6), 2,3-DHBA was
better at discriminating mutated from WT IDH1/2 than 2R-HG itself. These observations point to
the production of 2,3-DHBA by mutant IDH1 and 2. The metabolic synthesis of 2,3-DHBA from its
presumed precursor (3S)-hydroxy-2-oxobutanoic acid involves reduction of an α-keto (2-oxo) group to
a (2R)-hydroxy group, as in the formation of 2R-HG from 2-OG (Figure 4). There is no known direct
metabolic interchange between 2R-HG and 2,3-DHBA. In addition, there are relatively few citations
for 2,3-DHBA. The presence of this metabolite in human urine has been documented on a limited
number of occasions [38,40,58–62] and has also been described in the mouse [63] and a single dog with
insulin-dependent diabetes mellitus (IDDM) [38]. The observation of abnormal threonine metabolism
to 2,3-DHBA in both children and a dog with IDDM [38] raises the question as to whether or not our
observations of elevated plasma 2,3-DHBA in AML with mutated IDH1/2 could be due to diabetes.
The relationship between diabetes mellitus and myelodysblastic syndromes (MDS) has been examined
but there is no clear evidence that diabetes is a risk factor for MDS [64]. MDS can evolve into AML [65],
but only seven of our 51 patients had a previous diagnosis of MDS (Table S1). It is unlikely therefore
that IDDM with enhanced threonine catabolism [38] was an influence on elevated plasma 2,3-DHBA in
AML patients with mutated IDH1/2.
The principal implication of our findings is that neomorphic isocitrate dehydrogenase due to
mutations at IDH1R132 and IDH2R140 not only reduces 2-OG to 2R-HG but also the threonine
metabolite (3S)-hydroxy-2-oxobutanoic acid to 2,3-DHBA, two metabolic transformations that are
remarkably similar. The biological characteristics of 2,3-DHBA are not known and whether or not
this metabolite plays a role in AML pathogenesis is also undetermined. Therefore, whether or not
2,3-DHBA is an oncometabolite in AML remains to be determined. Moreover, regardless of any putative
pathobiological properties of 2,3-DHBA, in the patient group described here, 2,3-DHBA appeared to be
a better biomarker for IDH1/2 mutations than even 2R-HG. Future research will need to confirm our
findings in a larger genotyped cohort of AML patients and evaluate plasma 2,3-DHBA as a biomarker
for IDH1/2 mutation. The occurrence of 2,3-DHBA has mostly been reported in urine and therefore
urinary 2,3-DHBA should also be evaluated for this biomarker. In addition, the biochemical conversion
of (3S)-hydroxy-2-oxobutanoic acid into 2,3-DHBA requires confirmation in cell lines expressing IDH1
and IDH2 mutated enzymes. Furthermore, what role if any that 2,3-DHBA plays in modifying the
epigenetic landscape of AML has not been investigated. Additionally, the pathogenetic properties of
2,3-DHBA will require investigation in AML and in other cancers where neomorphic IDH is known to
play a role. Finally, and importantly, it remains to be established if knowledge of either 2,3-DHBA
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or 2R-HG plasma levels has clinical implications for the treatment of AML in patients in addition to
IDH1 or IDH2 genotype. It is not the mutant genotypes per se that modify AML epigenetics, rather
the oncometabolite 2R-HG. It has been established in this report that plasma levels of both 2R-HG
and 2,3-DHBA are highly variable, both in WT and mutated IDH1/2 patients. Therefore, plasma levels
of these metabolites may have a significant bearing on the outcome and for the therapy of AML.
Newly approved mutant IDH1 inhibitors such as ivosidenib can be used to treat relapsed or refractory
IDH1-mutant AML [66]. The relapse of such patients after ivosidenib therapy has been reported
to be due in part to new mutations occurring in the IDH1 and IDH2 genes [67]. This would be a
circumstance where monitoring of plasma or urinary 2R-HG and 2,3-DHBA concentrations throughout
therapy would provide a measure of drug efficacy that relies upon inhibition of mutant IDH1 and
suppression of 2R-HG production. When plasma 2R-HG levels were monitored during a dose-ranging
pharmacokinetic investigation of ivosidenib, 2R-HG levels were maximally and persistently inhibited
in most, but not all, patients with advanced hematologic malignancies treated with 500 mg QD
ivosidenib [68]. This demonstrates the value of such metabolic biomarkers in a precision medicine
approach to drug treatment. In the same way, valuable insights into the progression of AML and its
mechanisms could be obtained through the use of plasma 2R-HG and 2,3-DHBA as biomarkers.
4. Materials and Methods
4.1. Investigation of AML Patients
AML patients diagnosed and treated at the Inselspital University Hospital, Bern, Switzerland
between 2009 and 2016 were included in this study. Informed consent of all patients in the study
was obtained according to the Declaration of Helsinki, and the studies were approved by the ethics
committee of Canton Bern, Switzerland (decision number #223/15). A total of 51 patients were recruited
(30M, 21F) with a mean ± S.D. age of 62.8 ± 8.9 (range 40–82) years. Patient details are given in Table S1.
Routine mutational screening for myeloid panel genes including FLT3, NPM1 and TP53 genes
and conventional karyotype analysis of at least 20 metaphases were performed for each patient by the
diagnostic department. Peripheral blood mononuclear cells (PBMCs) and bone marrow mononuclear
cells (BMMCs) were collected at the time of diagnosis before the commencement of treatment.
4.2. Genotyping IDH1,2 and D2HGDH
Genomic DNA was extracted from PBMCs or MBBCs. DNA fragments were amplified using
FIREPol (Solis Biodyne) and gene-specific primers. For the IDH1 gene, the primers were IDH1-F
(5′- CCACCAACGACCAAGTCACCA-3’) and IDH1-R (5’-CAACATGACTTACTTGATCCCCA-3′).
For the IDH2 gene, the primers were IDH2-F (5′-CTCTGTCCTCACAGAGTTCAAGCT-3′) and
IDH2-R (5′-GCCCGGTCTGCCACAAAGTCTGT-3′). For the D2HGDH gene, the primers were
designed to cover the regions with the known mutations A208T, R212W, R421H, A426T,
I147S, D375Y, N439D and V444A [43,44]. To cover A208T and R212W, the primers were F1
(5′-GGAGCTGAGCCGGTATGTGGAGGA-3′) and R1 (5′-GCCCATGAGAGCCGTGAGAGGACA-3′).
R421H and A426T were covered with the primers F2 (5′-CTCGTCTCATCCTCTAGATGCT-3′) and
R2 (5′-CTGCCCTGCCTCGAAGCCT-3′), I147S with F3 (5′-GGGGATGGTGGCGTAGGGGT-3′) and
R3 (5′-CCCACAGTTGCAGACGCTGGCA-3′), D375Y with F4 (5′-CAGGCTCCAACGCAGGCCA-3′)
and R4 (5′-CCCACACTGTCTAGGCTGCACCA-3′). N439D and V444A were covered with primers F5
(5′-GCCGGGGGTCTCGGGGT-3′) and R5 (5′-GCCCAGGACGTCCCTCTTCCT-3′). DNA sequences
were analyzed by Sanger sequencing using the gene-specific primers.
4.3. Gene Expression Analysis Using Taqman Assays
RNA was extracted from mononuclear cells isolated from peripheral blood or bone marrow of
AML patients and quantified using Taqman gene expression assays by Applied Biosystems, Thermo
Fisher Scientific, Waltham, MA, USA. Total RNA was extracted using the Nucleospin RNAplus kit
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(740984.50, Macherey-Nagel, Düren, Germany). RNA was reverse transcribed using random primer
and MMLV-RT (Promega, Madison, WI, USA). Relative quantitation was performed on the ABI7500
Real-Time PCR Instrument using FAST Start Universal probe master mix (Roche, Switzerland) and
gene-specific Taqman probes provided by Thermofisher: Hs00292260_m1 (D2HGDH), Hs01560299_m1
(SLC16A1), Hs00358829_m1 (SLC16A3), Hs00537914_m1 (SLC22A6), Hs00188599_m1 (SLC22A8) and
Hs01104728_m1 (ABL1). Measurements for D2HGDH, SLC16A1 and SLC16A3 were normalized with
ABL1 values (ddCt relative quantitation). Assays were performed with four physical replicates each.
4.4. GC–MS Metabolomics of AML Plasmas
EDTA anticoagulated plasma was frozen at −20 ◦C until analyzed. Thawed aliquots of all samples
were pooled to create a series of quality control (QC) samples. Aliquots of plasma (50 µL) were subjected
to GC–MS analysis in triplicate with 4-chlorophenylacetic acid (2 µM; 100 µL) as internal standard after
the addition of ultrapure pyridine (200 µL; Merck, Darmstadt, Germany) and blown to dryness under
N2 at 40 ◦C using a slight modification of our published methods [69,70]. Dried plasmas in capped
glass tubes were then converted to their trimethylsilyl (TMS) derivatives with BSTFA containing 1%
TMCS (250 µL; Sigma-Aldrich Chemie GmbH, Buchs, Switzerland) and ultrapure pyridine (100 µL)
that was heated at 75 ◦C for 30 min, cooled and transferred to autoinjector vials. Derivatized plasmas
were analyzed in batches of 30 that included a QC samples for the first five injections and then after
every ten analytical samples. Samples (1.0 µL) were injected using an Agilent 7683B liquid sampler
into an Agilent 6890N gas chromatograph with an Agilent 5975B mass selective detector operating
under electron impact ionization at 70 eV. The front inlet was operated in splitless mode at 250 ◦C and
an HP5-MS column (60 m; i.d. 250 µm; film thickness 0.25 µm) subjected to a temperature program of
70 ◦C for 3 min, 10 deg/min to 300 ◦C, held for 8 min (run time 34 min). Mass spectra were collected
from m/z 35.0 to 650.0.
Raw chromatographic data yielded 67 chromatographic peaks that were annotated using the
AutoQuant routine in MSD ChemStation (F 01.03.2357), employing the NIST 14 spectral library (MS Wil
GmbH, Wil, Switzerland) that contained 276,248 mass spectra from 242,466 compounds. Confirmation
of metabolite identities was made by comparison of their retention times and mass spectra with an
in-house collection of 120 authentic standards. Six metabolites each appeared as two peaks due to
multiple TMS derivatives and these concentrations were summed to yield relative concentrations
(peak area ratio with the internal standard) for 60 identified metabolites. A spreadsheet of relative
concentrations for each metabolite was constructed using Quant Browser GCMS software (Leoson BV,
Middelburg, The Netherlands) [69,70], which was then imported into SIMCA 16 (Sartorius Stedim,
Goettingen, Germany) for multivariate data analysis.
4.5. Multivariate Data Analysis and Univariate Statistics
Datasets (WT IDH1/2, IDH1R132, IDH2R140, and QC) were first analyzed by multivariate data
analysis using unsupervised principal components analysis (PCA) to examine the internal structure of
the datasets and the occurrence of any outliers in the PCA scores plots [32]. Next, data were assigned
to classes (WT IDH1/2, IDH1R132, IDH2R140, and QC) and subjected to supervised analysis using
partial least squares projection to latent structures-discriminant analysis (PLS-DA) to test for clustering
and segregation of the different datasets in PLS-DA scores plots [32]. The PLS-DA models were tested
for potential overmodeling by a cross-validation procedure that repetitively (200 iterations) removed
1/7 of the data, randomized the remaining 6/7 and returned the 1/7 previously removed. The R2
(correlation) and Q2 (predictability) coefficients should degrade to <0.3 and <0, respectively, if the
data are not overmodeled [70]. After validating the PLS-DA models, data were finally subjected to
orthogonal PLS-DA (OPLS-DA), where the loadings can be expressed in the form of an S-plot that
shows metabolites that are up- and down-regulated in different datasets [70–73]. Metabolites selected
by OPLS-DA were then subjected to univariate statistics using GraphPad Prism 8.4.3. All statistical
determinations were nonparametric to allow for non-Gaussian distribution of data. Specifically,
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for comparison between groups, a two-tailed Mann–Whitney test was used to compare median values
with p-value cut offs for statistical significance lowered below p = 0.05 by use of the Bonferroni
correction for multiple comparisons [74]. For correlations between datasets, Spearman rank correlation
was used. Receiver operating characteristic (ROC) curves were also generated using Prism.
Raw GC–MS data are available at http://doi.org/10.6084/m9.figshare.13014278.
5. Conclusions
It is concluded that mutant isocitrate dehydrogenase IDH1R132 and IDH2R140 in AML patients
not only metabolically reduces 2-oxoglutaric acid to the oncometabolite (2R)-hydroxyglutaric acid
(2R-HG) but also elicits the reduction of the threonine metabolite (3S)-hydroxy-2-oxobutanoic acid
to (2R,3S)-dihydroxybutanoic acid (2,3-DHBA). The products of both reactions bear chemical and
stereochemical similarities. The two metabolic products were highly statistically significantly elevated
in the plasma of AML patients with IDH1R132 and IDH2R140 mutations compared to patients with
wild-type IDH1/2. These two plasma metabolites were strongly correlated across all patients studied.
D-2-Hydroxyglutarate dehydrogenase (D2HGDH) inactivating alleles are unlikely to explain elevated
both 2R-HG and 2,3-DHBA plasma concentrations in AML patients that are WT for IDH1/2 since
the expression of D2HGDH did not correlate with 2R-HG and 2,3-DHBA plasma concentrations.
ROC analysis established that 2,3-DHBA was a better biomarker for IDH1/2 mutation in AML than
2R-HG. Metabolomic analysis revealed major differences in the plasma metabolome between WT
IDH1/2, IDH1R132 and IDH2R140 patients, with 21 metabolites displaying statistically significant
differential plasma concentrations in the order IDH2R140 > WT IDH1/2 > IDH1R132. These were mostly
α-amino acids and urea cycle intermediates, suggesting differential effects of these two mutations
on AML biology. In addition to a potential role as a plasma biomarker for IDH1/2 mutation in AML,
this little studied metabolite 2,3-DHBA may play an etiological role in leukemogenesis. Plasma 2R-HG
and 2,3-DHBA as biomarkers may assist in monitoring drug therapy for AML and enhance our
understanding of disease progression and relapse.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/10/2842/s1,
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Figure S2: Correlations between SLC16A1 and SLC16A3 mRNA expression and 2R-HG and 2,3-DHBA plasma
concentration, Table S1: Patient characteristics, Table S2: Triplicate plasma relative concentrations of 60 metabolites
for each AML patient, Table S3: AML clinical variables and effect on the plasma metabolome.
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